Red blood cell alloimmunization: New findings at the bench and new recommendations for the bedside

Current Opinion in Hematology

Volumn 23, Issue 6, 2016, Pages 543-549

  Hendrickson, Jeanne E ^a   Eisenbarth, Stephanie C ^a   Tormey, Christopher A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

hemolytic disease of the newborn; red blood cell alloimmunization; transfusion

Indexed keywords

ALLOANTIBODY; BIOLOGICAL MARKER; CD4 ANTIGEN; HLA ANTIGEN; ANTIGEN;

ALLOIMMUNIZATION; ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; ERYTHROCYTE TRANSFUSION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; INFLAMMATION; NEWBORN HEMOLYTIC DISEASE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RECIPIENT; REVIEW; ANIMAL; ANIMAL MODEL; BLOOD TRANSFUSION; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTE; GENETICS; IMMUNIZATION; IMMUNOLOGY; RESEARCH; RISK FACTOR; SEROEPIDEMIOLOGY; TRANSFUSION REACTION;

ANIMALS; ANTIGENS; BLOOD TRANSFUSION; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTES; HUMANS; IMMUNIZATION; ISOANTIBODIES; MODELS, ANIMAL; RESEARCH; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; TRANSFUSION REACTION;

EID: 84979700574     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000277     Document Type: Review

References (57)

1. Hendrickson JE, Tormey CA. Red blood cell antibodies in hematology/ oncology patients: Interpretation of immunohematologic tests and clinical significance of detected antibodies. Hematol Oncol Clin North Am 2016; 30:635-651.
2. Nickel RS, Hendrickson JE, Fasano RM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: A case series. Transfusion 2016; 56:107-114.
3. Hendrickson JE, Delaney M. Hemolytic disease of the fetus and newborn: Modern practice and future investigations. Transfus Med Rev 2016. [Epub ahead of print].
4. Caamano J, Musante E, Contreras M, et al. Frequency and specificity of red blood cell alloimmunization in Chilean transfused patients. Transfus Med Hemother 2015; 42:4-7.
5. Ngoma AM, Mutombo PB, Ikeda K, et al. Red blood cell alloimmunization in transfused patients in sub-Saharan Africa: A systematic review and metaanalysis. Transfus Apher Sci 2016; 54:296-302.
6. Gehrie EA, Tormey CA. The Influence of clinical and biological factors on transfusion-associated non-ABO antigen alloimmunization: Responders, hyper-responders, and nonresponders. Transfus Med Hemother 2014; 41:420-429.
7. Babiker HA, Elsayed TY. Frequency of alloantibodies among chronic renal failure patients in red sea state. Indian J Hematol Blood Transfus 2014; 30:187-190.
8. Verduin EP, Brand A, Middelburg RA, et al. Female sex of older patients is an independent risk factor for red blood cell alloimmunization after transfusion. Transfusion 2015; 55:1478-1485.
9. Zalpuri S, Evers D, Zwaginga JJ, et al. Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion 2014; 54:1981- 1987.
10. Dhawan HK, Kumawat V, Marwaha N, et al. Alloimmunization and autoimmunization in transfusion dependent thalassemia major patients: Study on 319 patients. Asian J Transfus Sci 2014; 8:84-88.
11. Azarkeivan A, Ahmadi MH, Zolfaghari S, et al. RBC alloimmunization and double alloantibodies in thalassemic patients. Hematology 2015; 20:223- 227.
12. Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122:1062-1071.
13. Sippert E, Fujita CR, Machado D, et al. Variant RH alleles and Rh immunisation in patients with sickle cell disease. Blood Transfus 2015; 13:72-77.
14. Silvy M, Tournamille C, Babinet J, et al. Red blood cell immunization in sickle cell disease: Evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica 2014; 99:e115-e117.
15. Ryder AB, Zimring JC, Hendrickson JE. Factors influencing RBC alloimmunization: Lessons learned from murine models. Transfus Med Hemother 2014; 41:406-419.
16. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2015; 168:291-300.
17. Telen MJ, Afenyi-Annan A, Garrett ME, et al. Alloimmunization in sickle cell disease: Changing antibody specificities and association with chronic pain and decreased survival. Transfusion 2015; 55:1378-1387.
18. Ryder AB, Hendrickson JE, Tormey CA. Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization. Br J Haematol 2015. [Epub ahead of print]
19. Richards AL, Hendrickson JE, Zimring JC, et al. Erythrophagocytosis by plasmacytoid dendritic cells and monocytes is enhanced during inflammation. Transfusion 2016; 56:905-916.
20. Arnon TI, Horton RM, Grigorova IL, et al. Visualization of splenic marginal zone B-cell shuttling and follicular B-cell egress. Nature 2013; 493:684-688.
21. Yi T, Li J, Chen H, et al. Splenic dendritic cells survey red blood cells for missing self-CD47 to trigger adaptive immune responses. Immunity 2015; 43:764-775.
22. Calabro S, Gallman A, Gowthaman U, et al. Bridging channel dendritic cells induce immunity to transfused red blood cells. J Exp Med 2016; 213:887- 896.
23. Elayeb R, Tamagne M, Bierling P, et al. Red blood cell alloimmunization is influenced by the delay between Toll-like receptor agonist injection and transfusion. Haematologica 2016; 101:209-218.
24. Kerbrat S, Vingert B, Junier MP, et al. Absence of the adaptor protein PEA-15 is associated with altered pattern of Th cytokines production by activated CD4' T lymphocytes in vitro, and defective red blood cell alloimmune response in vivo. PLoS One 2015; 10:e0136885.
25. Vingert B, Tamagne M, Habibi A, et al. Phenotypic differences of CD4(') T cells in response to red blood cell immunization in transfused sickle cell disease patients. Eur J Immunol 2015; 45:1868-1879.
26. Nickel RS, Horan JT, Fasano RM, et al. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. Am J Hematol 2015; 90:1135-1141.
27. Zhong H, Bao W, Friedman D, et al. Hemin controls T cell polarization in sickle cell alloimmunization. J Immunol 2014; 193:102-110.
28. Dinardo CL, Fernandes FL, Sampaio LR, et al. Transfusion of older red blood cell units, cytokine burst and alloimmunization: A case-control study. Rev Bras Hematol Hemoter 2015; 37:320-323.
29. Hogervorst E, Middelburg R, Brand A, et al. Anti-K formation is not associated with the storage time of transfused red blood cells. Transfusion 2015; 55:1472-1477.
30. Desai PC, Deal AM, Pfaff ER, et al. Alloimmunization is associated with older age of transfused red blood cells in sickle cell disease. Am J Hematol 2015; 90:691-695.
31. BaleottiWJr, Ruiz MO, Fabron A Jr, et al. HLA-DRB1-07:01 allele is primarily associated with the Diego a alloimmunization in a Brazilian population. Transfusion 2014; 54:2468-2476.
32. Schonewille H, Doxiadis II, Levering WH, et al. HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies. Transfusion 2014; 54:1971-1980.
33. Tatari-Calderone Z, Gordish-Dressman H, Fasano R, et al. Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease. Hum Immunol 2016; 77:35-40.
34. Unni N, Peddinghaus M, Tormey CA, et al. Record fragmentation due to transfusion at multiple healthcare facilities: A risk factor for delayed hemolytic transfusion reactions. Transfusion 2014; 54:98-103.
35. Harm SK, Yazer MH, Monis GF, et al. A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol 2014; 141:256-261.
36. Haspel RL, Driscoll A, Kurbaj H, et al. Transfusion medicine illustrated. The antibody identification card in action. Transfusion 2015; 55:2551.
37. Schwickerath V, Kowalski M, Menitove JE. Regional registry of patient alloantibodies: First-year experience. Transfusion 2010; 50:1465-1470.
38. Casas J, Friedman DF, Jackson T, et al. Changing practice: Red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion 2015; 55:1388-1393.
39. Schonewille H, Honohan A, van der Watering LM, et al. Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: A randomized trial (MATCH study). Transfusion 2016; 56:311-320.
40. Sandler SG, Flegel WA, Westhoff CM, et al. It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. Transfusion 2015; 55:680-689.
41. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, Blood Institute. Evidence-based management of sickle cell disease: Expert panel report 2014. Washington, DC: US Department of Health and Human Services, National Institutes of Health; National Heart, Lung and Blood Institute; 2014; http://www.nhlbi.nih.gov/health-pro/guide lines/sickle-cell-disease-guidelines/ [cited 1 June 2016].
42. Kacker S, Ness PM, Savage WJ, et al. Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients. Transfusion 2014; 54:86-97.
43. Tormey CA, Hendrickson JE. Routine non-ABO blood group antigen genotyping in sickle cell disease: The new frontier in pretransfusion testing?. Transfusion 2015; 55:1374-1377.
44. Kacker S, Vassallo R, Keller MA, et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. Transfusion 2015; 55:2095-2103.
45. Fasano RM. Hemolytic disease of the fetus and newborn in the molecular era. Semin Fetal Neonatal Med 2016; 21:28-34.
46. Schonewille H, Prinsen-Zander KJ, Reijnart M, et al. Extended matched intrauterine transfusions reduce maternal Duffy, Kidd, and S antibody formation. Transfusion 2015; 55:2912-2919.
47. Goldman M, Lane D, Webert K, et al. The prevalence of anti-K in Canadian prenatal patients. Transfusion 2015; 55:1486-1491.
48. Solheim BG. Provision of K- (KEL1-) blood to women not more than 50 years of age. Transfusion 2015; 55:468-469.
49. O'Brien KL, Kim YA, Haspel RL, et al. Provision of KEL1-negative blood to obstetric patients: A 3-year single-institution retrospective review. Transfusion 2015; 55:599-604; quiz 598.
50. Kapur R, Della Valle L, Sonneveld M, et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: A new variable predicting severity in haemolytic disease of the fetus and newborn. Br J Haematol 2014; 166:936-945.
51. Sonneveld ME, Natunen S, Sainio S, et al. Glycosylation pattern of antiplatelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia. Br J Haematol 2016; 174:310-320.
52. Kapur R, Della Valle L, Verhagen OJ, et al. Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D. Transfusion 2015; 55:553-562.
53. Stowell SR, Arthur CM, Girard-Pierce KR, et al. Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model. Haematologica 2015; 100:e394-e397.
54. Bernardo L, Yu H, Amash A, et al. IgG-mediated immune suppression to erythrocytes by polyclonal antibodies can occur in the absence of activating or inhibitory Fcgamma receptors in a full mouse model. J Immunol 2015; 195:2224-2230.
55. Bergstrom JJ, Heyman B. IgG suppresses antibody responses in mice lacking C1q, C3, complement receptors 1 and 2, or IgG Fc-receptors. PLoS One 2015; 10:e0143841.
56. Bakchoul T, Greinacher A, Sachs UJ, et al. Inhibition of HPA-1a alloantibodymediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: Toward targeted treatment of fetal-alloimmune thrombocytopenia. Blood 2013; 122:321-327.
57. Zdravic D, Yougbare I, Vadasz B, et al. Fetal and neonatal alloimmune thrombocytopenia. Semin Fetal Neonatal Med 2016; 21:19-27.